Humacyte Q4 EPS $(0.24), Inline; Humacyte Says Its Cash And Cash Equivalents Of $80.4M, Net Proceeds Of $43.1M From The March Offering And Additional Draw Of $20M Under The Oberland Funding Arrangement, Will Provide Cash Runway For At Least 12 Months
Humacyte第四季度每股收益爲0.24美元（0.24），內聯；Humacyte表示，其現金及現金等價物爲8,040萬美元，3月份發行的淨收益爲4,310萬美元，以及根據Oberland融資安排額外提取的2000萬美元，將爲至少12個月的現金流提供資金